Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.
2.

Targeting the MET gene for the treatment of non-small-cell lung cancer.

Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.

Crit Rev Oncol Hematol. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006. Epub 2013 Dec 1. Review.

PMID:
24355409
3.

New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.

Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W.

Clin Cancer Res. 2011 Sep 1;17(17):5530-7. doi: 10.1158/1078-0432.CCR-10-2571. Epub 2011 Jul 20. Review.

4.

[EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].

Moldvay J, Peták I.

Magy Onkol. 2012 Mar;56(1):38-49. doi: MagyOnkol.2012.56.1.38. Epub 2012 Jan 15. Hungarian.

5.

Epidermal growth factor receptor mutations in lung cancer.

Sharma SV, Bell DW, Settleman J, Haber DA.

Nat Rev Cancer. 2007 Mar;7(3):169-81. Review.

PMID:
17318210
6.
7.

[The mechanisms of resistance to EGFR-TKIs and challenges to overcome resistance in EGFR mutant non-small cell lung cancer].

Yamaoka T, Ohmori T.

Gan To Kagaku Ryoho. 2012 Jun;39(6):857-62. Review. Japanese.

PMID:
22705678
9.

Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.

Batus M, Fidler MJ, Bonomi PD.

Expert Rev Anticancer Ther. 2010 Oct;10(10):1589-99. doi: 10.1586/era.10.104. Review.

PMID:
20942630
10.

Investigation of acquired resistance to EGFR-targeted therapies in lung cancer using cDNA microarrays.

Kani K, Sordella R, Mallick P.

Methods Mol Biol. 2012;795:233-53. doi: 10.1007/978-1-61779-337-0_16.

PMID:
21960227
11.

Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.

Heuckmann JM, Rauh D, Thomas RK.

J Clin Oncol. 2012 Sep 20;30(27):3417-20. doi: 10.1200/JCO.2012.43.1825. Epub 2012 Aug 20. No abstract available.

12.

[Overcoming resistance to EGFR-TKI in lung cancer].

Takeda K.

Gan To Kagaku Ryoho. 2009 Apr;36(4):552-6. Japanese.

PMID:
19381026
13.

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.

Ladanyi M, Pao W.

Mod Pathol. 2008 May;21 Suppl 2:S16-22. doi: 10.1038/modpathol.3801018. Review.

14.

EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head.

Clark J, Cools J, Gilliland DG.

PLoS Med. 2005 Mar;2(3):e75. Epub 2005 Feb 22. No abstract available.

15.

Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies.

Joshi VA, Kucherlapati R.

Pharmacogenomics. 2007 Sep;8(9):1211-20. Review.

PMID:
17924836
18.

Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.

Dziadziuszko R, Jassem J.

Ann Oncol. 2012 Sep;23 Suppl 10:x193-6.

PMID:
22987961
19.

Drugging the bad "AKT-TOR" to overcome TKI-resistant lung cancer.

Settleman J, Kurie JM.

Cancer Cell. 2007 Jul;12(1):6-8. Review.

20.

Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy.

Okamoto I.

FEBS J. 2010 Jan;277(2):309-15. doi: 10.1111/j.1742-4658.2009.07449.x. Epub 2009 Nov 18. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk